Supportive care

Treatment of multiple myeloma bone disease: experimental and clinical data. Papamerkouriou YM et al. Expert Opin Biol Ther. 2014 Nov 12:1-18. [Epub ahead of print]. Bisphosphonates in multiple myeloma: a fractured consensus. Kumar SK. Leuk Lymphoma. 2014 Nov 5:1-2. [Epub ahead of print]. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Berenson JR et al. Support Care…

General

The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods. Kontodimopoulos N. Qual Life Res. 2014 Nov 13. [Epub ahead of print]. Prevalence of monoclonal gammopathy in HIV patients in 2014. Genet P et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19649. doi: 10.7448/IAS.17.4.19649. eCollection 2014.…

Complications of myeloma and its treatments

Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. Sullivan MR et al. J Clin Apher. 2014 Nov 21. doi: 10.1002/jca.21371. [Epub ahead of print]. A case of endocapillary proliferative glomerulonephritis with macrophages phagocytosing monoclonal immunoglobulin lambda light chain. Watanabe H et al. Pathol Int. 2014 Nov 19. doi: 10.1111/pin.12229. [Epub ahead of print]. Successful re-administration of lenalidomide after lenalidomide-induced…

Current treatments

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Ong SY et al. Br J Haematol. 2014 Nov 21. doi: 10.1111/bjh.13238. [Epub ahead of print]. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Clark RE et al. Blood…

Supportive care

Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Cerchione C et al. Support Care Cancer. 2014 Oct 24. [Epub ahead of print]. Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma. Oksman MJ et al. Bone Marrow Transplant. 2014 Oct…

General

Haematological cancer: Optimizing the treatment of multiple myeloma. Morgan GJ et al. Nat Rev Clin Oncol. 2014 Oct 28. doi: 10.1038/nrclinonc.2014.185. [Epub ahead of print]. The Role of Bendamustine in the Management of Plasma Cell Myeloma. Gertz MA. Leuk Lymphoma. 2014 Oct 27:1-5. [Epub ahead of print]. Non-hodgkin lymphoma risk and insecticide, fungicide and fumigant…

Complications of myeloma and its treatments

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Blimark C et al. Haematologica. 2014 Oct 24. pii: haematol.2014.107714. [Epub ahead of print]. Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy. Li J et al. Cell Biochem Biophys. 2014…

Current treatments

Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Tuchman SA et al. J Clin Apher. 2014 Oct 8. doi: 10.1002/jca.21360. [Epub ahead of print]. Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in chinese patients. Lin M et al. Adv Ther. 2014…